Lupuzor™ Gears Up To Start Pivotal Phase III trials

2nd October 2014 - 2:25 pm

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that Phase III activities of its lead compound Lupuzor™ will soon commence.

Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical trials. Before these initial activities are completed, it is expected that a further agreement to develop Lupuzo™ will be finalised and signed which will see Immupharma and the potential partner fund the phase III trials. This agreement will also allow the partner to run the phase III pivotal programme based on the strengthened study protocol agreed between ImmuPharma and the FDA.
Commenting on the announcement, ImmuPharma’s Chairman, Richard Warr, said: “Taking Lupuzor™ into pivotal Phase III trials represents a significant milestone in the history of ImmuPharma. Our strategy remains focused on maximising the full value of Lupuzor™ on behalf of our shareholders as we progress the compound through phase III and beyond.”
Dr Robert Zimmer, ImmuPharma’s President and Chief Scientific Officer, further commented: “The entry of Lupuzor™ into pivotal Phase III trials involves a potential partner with strong credentials and expertise in late stage clinical development. Furthermore they provide an independent validation of Lupuzor’s™ potential to become a leading treatment for lupus patients world-wide. We are commencing Lupuzor’s™ phase III activities immediately and look forward to providing further guidance on progress as soon as possible.”
Share this article

Leave a comment